siremadlin + donor lymphocyte infusion

**Siremadlin + donor lymphocyte infusion** is an investigational therapeutic regimen combining siremadlin, a **small molecule MDM2 inhibitor** that restores p53 tumor suppressor activity to promote cancer cell apoptosis[3][5][7][9], with **donor lymphocyte infusion (DLI)**, an adoptive immunotherapy in which lymphocytes from a stem cell or bone marrow donor are infused into the patient to induce antitumor immune effects (graft-versus-tumor/leukemia)[2][4][6][10]. This combination is considered for hematologic malignancies, particularly in patients who have relapsed after allogeneic stem cell transplantation, with siremadlin targeting tumor growth and DLI amplifying immune-mediated clearance of malignant cells.

Other names

donor lymphocyte infusionDLI